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Microbiology

Selection and Characterization of a 2',3'-dideoxycytidine-Resistant
Mutant of Feline Immunodeficiency Virus (63 pp)
Director; Thomas W. North
A mutant of feline immunodeficiency virus (FIV), designated DCR-2c,
was selected in cell culture in the continuous presence of 25 ^M
2',3'-dideoxycytidine (ddC). This mutant displayed a 5-fold
resistance to ddC, a 3-fold resistance to 2',3'-dideoxyinosine (ddl),
a 4-fold resistance to phosphonoformic acid (PFA), slight resistance
to 2',3'-dideoxy-3'-thiacytidine (3TC) and wild-type susceptibility
to 3'-azido-3'-dideoxythymidine (AZT) and 9-(2phosphonylmethoxyethyOadenine (PMEA) compared to the wild-type
molecular clone of FIV, 34TF10. This mutant, designated DCR-5c,
was plaque-purified by a modification of the procedure developed in
this lab. This plaque-purified mutant retained the phenotype of the
mutant population, DCR-2c. DCR-5c is similar to ddC-resistant
human immunodeficiency virus type 1 (HIV-1) in ddl crossresistance. It also has an RT resistant to ddCTP, like the HIV-1
mutant. The RT purified from DCR-5c demonstrated a 10-fold
resistance to ddCTP compared to wild-type RT. In addition, the
sequence of the RT-encoding region of DCR-5c was elucidated and
compared to FIV 34TF10. A single point mutation was found in the
ddC-resistant mutant that resulted in the amino acid substitution of
His for Asp-3. No drug resistant mutation has previously been
described in this area in either FIV or HIV-1. This mutation is in a
region consistent with altered binding of template-primer
contributing to resistance.
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INTRODUCTION

GENERAL INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus
and the causative agent of acquired immunodeficiency syndrome
(AIDS) (2,14).

The virus targets cells of the immune system,

specifically the helper T lymphocytes. Infected patients are
susceptible to many opportunistic infections due to the weakened
immune system.

HIV-1 is currently the number two killer of people

between the ages of 25 and 45 years. Over 13 million people are
infected with the virus today and predictions for the future are
frightening (33). Current research into control of the disease falls
into two categories: protective vaccines and chemotherapy. Vaccine
development has been slowed because of the antigenic diversity of
HIV-1. Research into chemotherapy for AIDS has achieved some
moderate success.

Four nucleoside analog inhibitors have been

approved by the Federal Drug Administration (FDA). However,
resistance to these FDA-approved drugs has arisen in clinical
treatment of AIDS patients. In addition, virus resistant to

experimental drugs have been selected in vitro. It is not known
whether or not drug-resistant variants are pathogenic, and this
question will significantly impact the course of therapy. In addition
to these molecular problems which have arisen with respect to the
virus, testing of new drugs and vaccines has presented ethical
problems with respect to human use. Although many activists
encourage experimental drug treatment in humans, the science
community has sought alternatives, such as in vitro systems and
animal models.

Due to the many obstacles stated above, an animal model is
essential. Not only is an animal model safer to work with for the
scientist, but in vivo pathogenesis studies can be performed. Many
animal models have been evaluated for use in studying HIV-1,
including Simian immunodeficiency virus (SIV), avian retroviruses,
murine retroviruses, severe combined-deficiency (SCID) mouse
models, Antiviruses in sheep, goats, horses and cows, HIV type 2
(HIV-2) infection in macaques, and feline immunodeficiency virus
(FIV).

Criteria that an animal model should meet include: 1)

naturally occurring disease, 2) relatively inexpensive, 3) non-

infective to humans, and 4) easily manipulated in in vitro and in vivo
studies (17). FIV has become recognized as a valuable animal model
for AIDS for several reasons; FIV causes a natural infection in cats
and a similar disease to human AIDS. The virus is not infectious to
humans, and cats are much more practical and economical to work
with than non-human primates. (17). FIV also offers both in vitro
and in vivo systems in which to study drug resistance.

FELINE IMMUNODEFICIENCY VIRUS
Feline immunodeficiency virus (FIV), a lentivirus, is the
etiological agent of a natural acquired immunodeficiency syndrome
(AIDS) in cats (36,37). This disease occurs in domestic cats, and
has also been produced by experimental infection of specificpathogen-free cats (52,58).

The virus is highly T lymphotrophic

which results in an immunodeficient state in the animal. Infected
cats are susceptible to many opportunistic diseases, as are humans
infected with HIV-1. FIV was first described in 1987 following
isolation from infected cats in a cattery. At first, many believed
the disease was caused by feline leukemia virus (FeLV), however, all
the animals in the cattery were seronegative for FeLV, therefore
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ruling out FeLV as the cause of this immunosuppressive disease (37).
Since the original identification of the disease, FIV has been shown
to be a worldwide infection of domestic cats.

FIV is

morphologically, as well as pathologically, similar to HIV-1.
Transmission of FIV to humans, however, has not been reported.
With these similarities in mind, FIV offers a unique opportunity to
study as an animal model for AIDS.

Life Cycle. FIV and HIV-1 share the prototypical life cycle of a
retrovirus (figure 1). The virus is first adsorbed by a receptor on
the host cell membrane. HIV-1 binds to the CD4 receptor on T cells.
A CD4 homologue, CD9 has been implicated in FIV binding and
infection (57). Once in the cell, the virus sheds its envelope and
releases its RNA genome along with other proteins, including the
enzyme reverse transcriptase (RT). This enzyme is unique to
retroviruses. RT is the virally encoded RNA-dependent DNA
polymerase responsible for synthesis of a DNA copy of the viral RNA
genome.

After synthesis of the complementary strand of DNA, the

enzyme has a second function, that of RNase H activity. The original
RNA strand is removed by this RNase H and a second strand of DNA is
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Figure 1. Retrovirus life cycle from virus entry to release (drawn by
David Hill).

synthesized by RT. Once the double-stranded DNA has been produced,
it is integrated by the viral protein integrase into the host genome
as a provirus (51). The provirus will remain dormant until some, as
of yet unknown, factor(s) stimulates the provirus into active
replication to produce infectious virus particles.

The cell will then

produce viral RNA and proteins. These progeny viruses assemble and
are released from the cell surface by budding. The virus can then
infect other cells.

Genome structure and organization.

FIV and HIV-1, are

enveloped, single-stranded RNA viruses. The FIV virion contains two
copies of its RNA genome which are held together by a dimer linkage
structure (DLS) near the 5' ends. The FIV genome consists of three
large open reading frames (orfs) corresponding to the main
structural genes, gag, pol and env (fig 2).

The three structural

genes are flanked by long terminal repeat (LTR) regions. There exists
an overlapping gag and pol coding sequence which is characteristic
of Antiviruses. In addition, the FIV genome also contains several
small orfs that are multiply spliced to generate genes that regulate
the expression of viral proteins (22,38,39,52). Coding regions of the
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Figure 2. Organization of the FIV genome.
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FIV genome have been identified that are responsible for
determining whether or not a viral infection is productive or latent
(22,38). These regions which encode the Rev protein and the Revresponsive element, are also found in HIV-1. Another small orf
contains a putative wT gene, that regulates viral infectivity and is
similar structurally and functionally to the vif gene of HIV-1 (52).
A putative tat orf has been described, (35,38,50) and may encode
the FIV equivalent to the transactivating protein of virus which
infect primates. No FIV counterpart to the HIV-1 nef gene has been
reported.

The entire FIV genome is approximately 9500 bases.

The gag

gene is reportedly 450 residues long and the calculated molecular
mass of the resulting polypeptide is 24 kDa. This agrees with
estimated mass of the core protein (p24) of FIV. The gag gene also
encodes for two small proteins (pi 0 and pi 7)(50).

The pol gene

encodes the enzymes reverse transcriptase, integrase, a protease,
and a protease-like protein (49) with dUTPase function (12) .

The

env gene of FIV, as with HIV-1, is located near the 3' end of the
genome. At least four small orfs exist. Two can be found in
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between the pol-env genes, and at least two are located in the env3' long terminal repeat (LTR) regions. The env gene is
approximately 750 base pairs long. Two env gene products of FIV
are synthesized from a 145 kDa precursor glycoprotein. The
precursor is quickly "trimmed" to a 130 kDa glycoprotein and is
further processed to two glycoproteins, gp95 and gp40.

Transmission and Pathogenesis.

Unlike HIV-1, sexual

transmission does not appear to be a major factor in the spread of
FIV. Transmission of FIV is generally through an infected cat biting
or scratching an uninfected cat. Experimentally-infected female
cats have been shown to transmit the virus to their offspring (56),
although naturally-infected cats transmitting virus to offspring has
not been reported. Vertical transmission is a significant mode of
transmission in HIV-1.

FIV infection causes an AIDS-like disease in cats that can be
broken down into five distinct stages. These stages correlate to the
levels of infection seen with HIV-1. The five clinical stages are
acute infection, asymptomatic carrier, persistent generalized
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lymphadenopathy, AIDS related complex (ARC) and AIDS (21). With
FIV the first signs of acute infection often include lymphadenopathy,
transient neutropenia, acute diarrhea and mild upper respiratory
signs (21). This correlates to the general lymphadenopathy and flu
like symptoms seen in early stages of HIV-1 infection (8). The acute
phase of each virus is of varying time lengths, and is followed by a
latent, asymptomatic phase. Virus has been detected during the
asymptomatic phase, and these cats are classified as asymptomatic
carriers. An extensive latent period of the FIV is seen in cats (up to
9 years) as is seen in humans infected with HIV-1 (average 6 years).
Cats generally show general lymphadenopathy concurrently with
clinical signs. Humans maintain a general lymphadenopathy while
appearing otherwise healthy. In cats, it appears that the generalized
lymphadenopathy stage is either extremely short or occurs at the
same time that ARC-like symptoms are occurring. The ARC stage in
cats and humans is characterized by chronic problems including
lymphadenopathy, stomatitis/gingivitis, skin disease, upper
respiratory disease, and/or enteric disease (5,21,36,). Neurological
disorders can accompany either ARC or AIDS stages of both diseases
(21). Cats progress to full-blown AIDS and die within eight months
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of the beginning of the ARC stage. Due to the similarity in pathology
of HIV-1 and FIV in their naturally occurring host, FIV is an obvious
model for in vivo pathogenesis studies.

Additionally, drug-resistant

isolates can be tested in vivo with FIV.

Treatment.

Due to the important role that RT plays in

replication of both HIV-1 and FIV, it is an obvious choice as a target
for antiviral chemotherapy.

Currently there are two groups of drugs

being studied for their inhibiting effect on RT:nucleoside analogs and
non-nucleoside analogs (fig 3). The non-nucleoside analogs are
noncompetitive inhibitors of RT and include phosphonoformic acid
(PFA), nevirapine, tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin2(1H)-one (TIBO). In addition, several protease inhibitors are also
being studied.

To date, the FDA has only approved nucleoside analogs for
treatment of humans with AIDS. The four RT inhibitors are the
nucleoside analogs: 3'-azido-3'-dideoxythymidine (AZT), 2',3'dideoxyinosine (ddl), 2',3'-dideoxycytidine (ddC), and 2',3'-dideoxy2',3'-didehydrothymidine (d4T). These nucleoside analogs are
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Figure 3. Nucleoside and pyrophosphate analogs with antiviral
activities.
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metabolized by the cell to the corresponding 5'-triphosphate. The
triphosphates are competitive inhibitors of HIV-1 and FIV RTs. The
metabolized triphosphates can also be incorporated into the
elongating DNA strand, causing termination of the chain (10). Since
both HIV-1 and FIV RT are susceptible to the nucleoside analog
inhibitors, FIV is an excellent choice as an animal model for drug
resistance studies.

Reverse transcriptase biochemical features.

Reverse

transcriptase is the main target for chemotherapy. Not only does
RT play an essential role in virus replication, it is also unique to the
virus.

FIV and HIV-1 RTs are very similar in physical properties,

catalytic activity and sensitivity to several RT inhibitors
(9,29,30,32).

The RT of FIV and HIV-1 are extremely similar in both

template specificity and

Mg2+

requirements (30). Our lab has

purified the RT from FIV and characterized the enzyme with respect
to its physical and catalytic properties (30). The purified FIV RT
consists of a p54-p66 heterodimer that is very similar to a p51-p66
heterodimer that can be generated in HIV-1 RT under proteolytic
conditions (11,27). Both HIV-1 and FIV RTs used similar amounts of
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Mg2+ for a given template. Although the RTs of HIV-1 and FIV
exhibited many similarities with respect to physical properties, it
has been shown that the two enzymes differ substantially in primary
sequence (30), as determined by peptide mapping and later confirmed
by DNA sequence (35,50). When the predicted amino acid sequence of
FIV RT was compared to that of HIV-1 RT, 60% identity was
observed (35). The similarity between the two enzymes creates an
opportunity to study RT inhibitors on a model lentivirus.

The susceptibilities of FIV RT and HIV-1 RT to various
inhibitors were also very similar. Inhibition constants for both
enzymes were determined for several inhibitors, and the two
enzymes were indistinguishable with respect to the following
inhibitors: 2',3'-dideoxythymidine 5'-triphosphate (ddTTP), NgdTTP,
2',3'-dideoxycytidine 5'-triphosphate (ddCTP), 2',3'-dideoxy-2',3'didohydrothymidine 5'-triphosphate (d4TTP), 3'-fluoro-3'deoxythymidine 5'-triphosphate (3'-F-dTTP), 3'-amino-3'deoxythymidine 5'-triphosphate (3'-NH2-dTTP) and two
noncompetitive inhibitors phosphonoformate (PFA) and
phosphonoacetate (PAA) (29). Due to the biochemical similarities of
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HIV-1 RT and FIV RT, FIV is also an excellent model for studying
drug resistance, especially since RT is the target for all approved
antivirals.

Drug Resistance.
treatment of AIDS.

Drug resistance is the limiting factor in the

AZT was the first drug approved and used for

treatment (28). Clinically, drug resistance to AZT (25), and
subsequently ddl and ddC has been reported (13,47).

Our lab was the

first to successfully select an AZT-resistant mutant of a lentivirus
in vitro (41). This was followed by the selection of AZT-resistant
mutants of HIV-1 in vitro (16,24). The AZT-resistant mutants of
FIV have similar phenotypic characteristics to the AZT-resistant
clinical isolates of HIV-1 (41). Resistance to AZT, ddl and ddC have
been traced to mutations within the RT-encoding region of the poi
gene of HIV-1 (19,20,26). The role of these mutations has been
studied through site-directed mutagenesis and structure/function
analysis of the RT.

Since the structure of HIV-1 RT was determined by
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crystallization, domains and binding sites within RT have been
identified. The crystal structure of FIV RT has not been determined,
however, due to the 68% similarity of amino acid sequence of the
two RTs, it is likely that structures are similar. The polymerase
domains of p66 and p51 each contain the same four domains, which
have been called finger, palm, thumb, and connection (23).

Most of

the mutations that confer resistance to nucleoside inhibitors have
been shown to reside in either the fingers subdomain or the palm
subdomain. Neither of these locations is in the immediate area of
the polymerase active site (3). Boyer et al. have proposed that
resistance to the dideoxynucleotide inhibitors results from a
repositioning or change in the conformation of the template-primer
binding to enzyme that alters the ability of the enzyme to select or
reject an incoming dNTP (3).

ddC-resistance of HIV-1 has been traced to multiple sites in
the RT encoding region of the pol gene. These include amino acids
65, 69, 74, 75, and 184(19,20,48,13). From analysis of the threedimensional structure of HIV-1, these sites have been mapped to
two places. Amino acids 65, 69, 74, and 75 all map within the
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fingers subdomain of RT and have been implicated in templateprimer interaction (3).

Amino acid 184 is near the polymerase

active site and may work by affecting the positioning of the
template-primer or by changing residues that directly interact with
incoming dNTPs.

ddC-resistant mutants of HIV-1 have arisen through selection
with ddC, ddl, 3TC and AZT (13,16,19,20,24,47). The phenotypes of
the ddC-resistant mutants of HIV-1 differ widely. ddC-resistant
mutants of HIV-1 that were selected by ddC treatment are well
described (15,16,19,20). One of these mutants was found to be
cross-resistant to ddl and 3TC. This ddC-resistant mutant of HIV-1
contained a lesion within the RT-encoding region of the po/gene. In
addition, Gu et al. have shown that the RT from the HIV-1 ddCresistant mutant has reduced sensitivity to ddCTP, 3TCTP, ddATP,
and AZTTP in vitro (19).

This RT exhibited a ten-fold resistance to

ddCTP compared to wild-type RT. This ten-fold resistance
corresponds to the ten-fold resistance the virus had to ddC. Gu et al.
have also selected a ddl-resistant mutant that was cross-resistant
to ddC (20). Judy Gobert in our lab has selected a ddl-selected
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mutant of FIV (classified as selected rather than resistant because
the virus was <5 fold resistant relative to wild-type). In contrast
to Wainberg's ddl-resistant mutant of HIV-1, the ddl-selected
mutant of FIV is hyper-sensitive to ddC and also cross-resistant to
PFA. In order to understand these data further we set out to select a
ddC-resistant mutant of FIV.

In order to study drug resistance, it is important to have a
defined system that is safe and easily manipulated. It is also useful
to have a system which allows for timely selection of drugresistant mutants. FIV has a well-defined cell culture system and
drug-resistant mutants can be selected readily (43). In addition,
there is a molecular clone of FIV, FIV 34TF10 with a known sequence
(50). This molecular clone provides a defined genetic system in
which to study mutations. Many of the questions raised by drug
resistance can be best answered in an animal model.

Not only can

drug-resistant mutants be selected and characterized in a cell
culture system, but the pathogenicity and infectivity of drugresistant mutants can be determined in cats (1).

Characterization
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of drug-resistant mutants of FIV offers insight into the mechanism
of drug-resistance in HIV-1 and can lead to the development of
better chemotherapeutic agents for AIDS.

SPECIFIC

AIMS

The goal of this study was to select and characterize a ddCresistant mutant of FIV 34TF10.

Specific objectives were to select

variants of FIV that emerge when virus replication occurs in the
presence of a high concentration of ddC, to determine whether virus
resistant to ddC are cross-resistant to other antivirals, and to
determine whether ddC-resistance is due to alterations in reverse
transcriptase. In addition, the foundation will be laid for studies in
cats, in which the pathogenicity of ddC-resistant FIV can be
examined.

MATERIALS AND METHODS

Chemicals. The dCTP, Triton X-100, aminoethyl carbazole,
RFA, -oligo(dC)io-i5, and ddC were purchased from Sigma Chemical
Co., St. Louis, Mo. AZT was provided by Philip A. Furman of Burroughs
Wellcome Co., Research Triangle Park, N.C. ddl was provided by the
Developmental Therapeutics Branch, Division of AIDS, National
Institute of Allergy and Infectious Diseases. 9-(2phosphonylmethoxyethyl)adenine (PMEA) was provided by H.-T. Ho of
Bristol Myers-Squibb Co., Wallingford, Conn.

2',3'-dideoxy-3'-

thiacytidine (3TC) was provided by Raymond Schinazi of Emory
University, Atlanta, Georgia. Poly(rA)-oligo(dT)io and Poly(rl) were
purchased from Pharmacia LKB, Piscataway, New Jersey.
International Bio Technologies (IBI) phenol for DNA extractions was
purchased from VWR Scientific. GeneAmp Polymerase Chain
Reaction (PCR) Core Reagents were purchased from Perkin Elmer
Cetus, Norwalk, CT. The Taq DyeDeoxy™ Terminator Cycle
Sequencing Kit was purchased from Applied Biosystems, Foster
City.CA. All other chemicals were reagent grade or better.
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Isotopes.

[5,-53H]-dCTP and [methyl-3H]dTTP were obtained

from Dupont-New England Nuclear, Boston, MA.

Cells and Virus. Virus derived from a molecular clone of the
Petaluma strain of FIV, 34TF10, was used in this study (50). Wildtype and mutant strains of FIV were grown and maintained in
Crandell feline kidney (CrFK) cells. Uninfected and infected cells
were grown in L & M medium which was composed of equal parts of
Leibovitz L-15 and Dulbecco's Modified Eagle Medium, supplemented
with 100 U of penicillin per ml, 100

fjg

of streptomycin per ml, 2.0

mM L-glutamine and 10% fetal bovine serum (FBS). FBS was heat
inactivated for 30 min. at 56° C.

All cultures were maintained at

37" C in a humidified 5% CO2 atmosphere. ddC-resistant FIV was
maintained in medium that contained 25 uM ddC, and the medium was
replaced with fresh medium and the appropriate concentration of
ddC every 2 days.

Virus stocks were prepared from medium containing
extracellular virus released from CrFK cells that had been infected
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with FiV for more than 21 days. Medium from confluent infected
cells was centrifuged at 500 X g for 10 min to remove cells.
Supernatants containing virus, were stored at -80° C in medium
containing! 0% dimethyl sulfoxide (DMSO). Aliquots of these stocks
were thawed and used to infect CrFK cells for subsequent studies.

Focal Infectivity Assay (FIA).

The FIA was developed in this

lab by Remington et al. (41) and is a modification of the FIA
developed by Chesebro and Wehrly to quantitate HIV-1 (6). In this
assay, 24-well plates were seeded with uninfected CrFK cells at a
density of 1.5 x 104 cells per well and incubated for one hour at 37°
C in growth medium or growth medium containing appropriate
concentration of drug. This incubation was to allow the cells to
convert drugs to their active form. These cells were infected with
FIV and allowed to grow to confluency (4-5 days). The medium was
replaced with fresh medium and appropriate drug concentration
every 2 days. When the cells reached confluency, the media was
aspirated and the cells were fixed with methanol for five minutes.
The cells were then washed twice with TNE (0.01 M Tris-HCI, pH 7.5
containing 0.15 M NaCI and 0.002 M EDTA), and once with TNE
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supplemented with 1% bovine serum. Immunostaining was done by
incubating the cells for 30 minutes at room temperature with 0.2 ml
of a 1/200 dilution of polyclonal cat anti-FIV that had been
obtained from FIV-infected specific-pathogen-free cats.

After the

incubation, cells were washed twice with TNE containing bovine
serum to remove excess anti-FIV. Next, the cells were incubated for
40 minutes with 0.2 ml of a 1/600 dilution of horseradish
peroxidase-conjugated goat anti-cat immunoglobulin (OrganonTeknika, Durham, NC.). The cells were again washed with TNE and
then stained with a solution of aminoethyl carbazole in sodium
acetate buffer, pH 5.0 (1 part per 19 parts buffer). The cells were
incubated with this substrate for 20 minutes in the dark. After
incubation, the cells were rinsed three times with water and
allowed to dry. Infected cells stained red against a clear
background. A group of four or more infected cells is defined as a
focus of infection. Foci were examined and counted under 10 to 40 X
magnification. For visualization, light was reflected off a piece of
ground glass to reduce the refractivity of the infected cells. For
dose response curves with drugs, data were plotted as a percentage
of control plaques (no drug) versus inhibitor concentration.
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Concentrations required to inliibit focus formation by 50% (IC50
values) were obtained directly from the linear portion of these
plots, using a computer-generated regression line. Within an
experiment, each point represents the mean of four determinations.

Selection of ddC-resistant mutant.

Two 25 cm2 flasks

containing CrFK cells at 60% confluency were pretreated for one
hour with 25

ddC to enable conversion of the drug to the active

form. Cells were infected with 0.9 ml of FIV 34TF10 (approximately
500 foci of infection per ml). These two cultures were maintained
by replacing medium and drug every two days and trypsinizing and
reseeding as necessary. The cultures were monitored weekly for
virus production by the FIA. When virus was detected in the
cultures, a second round of infection was initiated using virus from
the culture with the highest titer, designated DCR-2. Two new 25
cm2 flasks containing CrFK cells at 60% confluency were pretreated
for one hour with 25 ji/M ddC. After a one-hour incubation, the cells
were infected with 0.5 ml of DCR-2 virus containing 400 foci of
infection per ml. These cultures were maintained as described
above and monitored weekly for virus production through the FIA.
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When virus was detected and characterized, plaque-purification of
the mutant virus was initiated.

Plaque purification of ddC-resistant mutant.

Plaque

purification of the mutant virus was carried out with a modification
of the procedure described by Remington et al. (42).

Virus was

plaque purified from the second round of selection, using limiting
dilutions of virus in the FIA. Limiting dilutions of virus were used
to infect CrFK cells in 24-well plates in the presence of 25 a;M ddC.
After six days, each supernatant was transferred to a well of a new
plate which had been seeded with uninfected CrFK cells in medium
with 25 /iM ddC. To enhance virus adsorption, just prior to the
transfer of supernatants, cells of the new plate were treated with
medium containing 8 ^/g/ml of DEAE dextran for 20 minutes (this
medium did not contain fetal bovine serum). The original plate was
stained and examined for those wells that contained a single focus.
Corresponding wells of the subculture plate were incubated until the
cells reached confluency. The cells and supernatant from each well
(corresponding to a well that contained a single focus of infection)
were transferred to flasks and maintained in medium containing 25
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IjM ddC. Cultures were monitored weekly for virus production by
FIA. Only one culture yielded virus, and it was used for further
characterization, sequence analysis, and RT assays.

Enzymes. RT was purified from virions of FIV 34TF10 and
mutant FIV by a method developed by North et al. (30). Briefly,
virions were disrupted with Triton X-100 and enzyme was purified
by chromatography on DEAE-cellulose and phosphocellulose.

Enzyme activity assay.

During purification, RT was assayed

for activity as reported previously (29,30) with poly(rA)-oligo(dT)io
as the template-primer. Reactions were typically carried out in a
volume of 50 ij\ and contained 50 mM Tris-HCI, pH 8.5,10 mM
dithiothreitol, 0.05% Triton X-100, 250 (jg of bovine serum albumin
(nuclease-free) per ml, 6 mM MgClz, 80 mM KCI, 20 fjM [methyl3H]dTTP(33 uCi/ml), 0.5 Azeo units (U) of poly(rA)-oligo(dT)io per
ml, and appropriate amounts of RT. Samples containing 40 /il were
taken at 1 hour and spotted onto filters (no. 3, 2.3-cm diameter;
Whatman, Inc., Clifton, NJ) that had been presoaked with 5%
trichloroacetic acid-1% sodium pyrophosphate. Filters were dried,
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washed four times (at least 1 hour each) with 5% tricholoroacetic
acid-1% sodium pyrophosphate (4° C) and twice with 95% ethanoi,
dried and then counted in Liquifluor (Dupont-NEN Research Products,
Boston MA). One unit of RT is defined as the amount of enzyme
required to catalyze the incorporation of 1 nmol of dTMP per hour
into poly(rA)-oligo(dT)io at 37" C.

Enzyme inhibition assay. Inhibition of RT from the ddCresistant mutant by ddCTP was compared to inhibition of wild-type
recombinant FIV RT. Double-reciprocal plots were used to determine
kinetic constants (Km and Kj) with the template-primer poly(rl)oligo(dC)io-i5 and ddCTP as the inhibitor (30). Reactions were
typically carried out in a volume of 50 ^1 and contained 50mM TrisHCI, pH 8.5, 10 mM dithiothritol, 0.05% Triton X-100, 250 /yg of
bovine serum albumin (nuclease-free) per ml, 6 mM MgClz, 80 mM
KCI, varying activity of [5,-5'-3H]-dCTP (33, 16.5, 4.9, 3.3, 2.4, and
1.6 uCi/ml) corresponding to varying concentrations of.dCTP (20, 10,
6, 4, 3, and 2 pM), 0.5 AzeoU of poly(rl)-oligo(dC)io-i5 per ml,
varying concentrations of ddCTP (0, 100, 250, and 500 nM), and
appropriate amounts of RT.

Samples containing 40

were taken at
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1 hour and spotted onto filters (no. 3, 2.3-cm diameter; Whatman,
Inc., Clifton, NJ) that had been presoaked with 5% trichloroacetic
acid-1% sodium pyrophosphate. Filters were dried, washed four
times (at least 1 hour each) with 5% tricholoroacetic acid-1%
sodium pyrophosphate (4° C) and twice with 95% ethanol, dried and
then counted in Liquifluor (Dupont-NEN Research Products, Boston
MA).

Nucleic acid preparation.

Total cellular DNA containing

provirus was extracted from CrFK cells that were infected with
ddC-resistant FIV. Confluent monolayers of infected cells were
washed three times with TBS (25 mM Tris-HCI, pH 7.4 containing 5
mM KCI and 137 mM NaCI) and removed from flasks (cells peel from
flask wall during the last wash). Cells were pelleted at 500 X g for
10 min. The cells were washed once with TE (lOmM Tris-HCI, pH 7.6
containing 1 mM EDTA), then resuspended in this buffer. Cell
suspensions were treated with 0.1 mg/ml Proteinase K and 0.5% SDS
overnight at 37" C. The cell lysates were then extracted three times
with phenol that had been equilibrated with 10 mM Tris-HCI, pH 7.5
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containing 100 mM NaCI and 1 mM EDTA. The aqueous phase was
collected and dialyzed against four changes of 10 mM Tris-HCI, pH
7.5 containing 100 mM NaCI and 1 mM EDTA until the A260 of the
dialysate was less than 0.16. The dialyzed aqueous phase was
treated with RNase A (0.1 mg/ml) at 37° C for 3 hours. The RNase
A-treated aqueous phase was extracted with one-half volume
equilibrated phenol and one-half chloroformrisoamyl alcohol (24:1).
The aqueous layer was removed and then extracted with an equal
volume of chloroform:isoamyl alcohol (24:1). The salt concentration
was adjusted by adding 1 /30 volume of 3 M Sodium acetate, pH 5 to
the aqueous phase. The DNA was precipitated by adding 3 volumes of
cold 95% ethanol and incubating overnight at -20° C. The
precipitated DNA was removed from the ethanol and allowed to dry.
The DNA was resuspended in sterile water and used for
amplification using the polymerase chain reaction (PGR).

PGR amplification and nucleotide sequence analysis.
Amplification of the RT-encoding region of the pol gene was
performed using the Perkin-Elmer/Getus GeneAmp PGR protocol.
Each 100 ^1 reaction contained 10 mM Tris-HGI, pH 8.3, 50 mM KGI,

200 tjM of each dNTP (dATP, dlTP.dCTP and dGTP), 4 mM MgClz, 0.2
A/M of each primer, 2.5 Units of AmpliTaq® DNA polymerase, and 1020 ^jg of target DNA. Reactions were overlaid with 50-100 ul of
light mineral oil. The sense primer (5'-GTA ATG TTT GTG TCT TAG
AAG ATA ACT C-3') and the reverse complement primer (5'-ATC
ATA TCC TGC ATC TTC TGA CCT-3') were synthesized in the Murdock
Molecular Biology Facility, University of Montana, Missoula, MT. The
primers were chosen to amplify a 1763 base pair fragment that
contained nucleotides 2268 through 4031. The PCR was run for 30
cycles, each cycle comprised of 30 seconds of denaturation at 94" C,
30 seconds of annealing at 62° C and two minutes of extension at
72° C. After PCR, the product was visualized on an agarose gel. For
this, the mineral oil was separated from the PCR products and an
aliquot of the mixture was run on a 0.8% low-melting agarose
electrophoresis gel in 40 mM Tris acetate, pH 7.6 containing 1 mM
EDTA (45). The agarose gel and running buffer contained 0.5

pg/ml

ethidium bromide. A 1763 base pair band was identified by
comparing the electrophoresed PCR reaction to a 1 Kb DNA ladder
(Gibco BRL, Gaithersburg.MD). The remaining PCR product was
purified using the QIAquick PCR Purification Kit, Qiagen Inc.,
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Chatsworth, CA.

Sequencing was performed In the forward and

reverse directions with two or more primers covering each 250 base
pair section of the RT-encoding region along with small flanking
regions on either end of RT. Four different primers were used to
sequence the 2342 region containing the point mutation. This DNA
was directly sequenced by Joan Strange, The Murdock Molecular
Biology Facility, The University of Montana, Missoula, MT, with a Taq
DyeDeoxy™ Terminator sequencing kit and analyzed on a Model 373A
automated DNA sequencer (Applied Blosystems, Foster City, CA).
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RESULTS

SELECTION OF ddC-RESISTANT MUTANT
A ddC-resistant mutant of FIV was selected by infection of
CrFK cells with FIV 34TF10 in the presence of inhibitory
concentrations of ddC. For the initial round of selection, two 25 cm2
flasks of cells were infected with a high multiplicity

of infection

(450 focal forming units/flask). The cells were pretreated with 25
/iM ddC for one hour prior to infection to ensure that the drug had
been converted to its active form by the cells. Cells were
maintained with 25 juM ddC throughout the selection by replacing
media and drug every two days. The drug concentration (25 ^JM) used
in this experiment was chosen because it is five times the

IC50

value and should inhibit wild-type virus production completely.
Cultures were monitored weekly for virus production by the FIA. No
virus was detectable until 17 weeks post infection. It should be
noted that virus production in other drug selections (AZT, ddl, PFA
and FLT) usually takes between 3 and 8 weeks. One of the cultures,
DCR-2C, was chosen to characterize and to continue selection. Once
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it was established that the virus was resistant to ddC, a second
round of selection was initiated (Figure 4). In addition, DCR-2c was
characterized with respect to other antivirals'(Table 1).

Two or

more dose response curves were performed using ddC and ddl. One
dose response curve for each of the other antiviral drugs were
performed for preliminary screening of the ddC-resistant phenotype.

For the second round of selection, 200 focal forming units of
undiluted cell-free virus/flask from the first round were used to
infect two 25 cm2 flasks of CrFK cells that had been pretreated with
25 A/M ddC. Less virus was used in the second round of selection to
lower the chance of heterogeneity that might arise from mixed
infections. The second round cultures were maintained with 25 //M
ddC and monitored for virus production as before. When virus was
detected, the second round was characterized (Table 1) and ddCresistance was confirmed (Figure 4). The same dose response curve
protocol as the first round was repeated with this round. Plaquepurification of the mutant virus was initiated.
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ddC DOSE RESPONSE CURVE
FOR DCR-2C AND 34TF10
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Figure 4. Inhibition of FIV 34TF10 and DCR-2c (Rounds 1 and 2 of
selection) by ddC as determined by focal infectivity assay. Results
are from two experiments and each point represents four
determinations. Bars represent standard error of the mean, and are
omitted where the standard error was to small to accurately show
using error bars.
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Table 1.

Sensitivities of FIV34TF10 and DCR-2c to antiviral
compounds as determined by FIAa.
Mean IC50 (jjM) ± SE

Compound

34TF10

DCR-2c
Round 1

DCR-2c
Round 2

ddCb

4.9+0.7

30+2

25±1

ddlb

5.5+0.8

21±1

23±2

AZT

0.34

0.62

0.50

PFA

113

>400

>400

PMEA

0.47

0.37

0.44

3TC

0.58

0.75

0.65

a Values represent four determinations per experiment
b Values are from two or more experiments.

PLAQUE PURIFICATION OF ddC RESISTANT MUTANT
In an effort to minimize the degree of heterogeneity within the
DCR-2C mutant population, the FIA was used to isolate a clone of
virus that had descended from a single infectious particle. A focus
of infection represents an infection by a single virion (Fig 5). CrFK
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Figure 5. Focus of FIV-infected CrFK cells detected with polyclonal
antiserum to FIV and peroxidase-conjugated goat anti-cat
immunoglobulin.
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cells were seeded at a density of 1.0 X 104 cells per well in TC24
plates and were infected with virus stocks that had been diluted to
contain approximately one infectious particle per well. After six
days, culture supernatants were transferred to uninfected cells in
TC24 plates, and the original plates were immunostained to identify
those wells that contained a single focus of infection. Cells
infected with progeny from a single infection event were
transferred along with supernatant to a flask and maintained with
25 ijM ddC and monitored for virus production by the FIA. Plaquepurification of the ddC-resistant mutant proved to be difficult. The
first three times plaque-purification of DCR-2c was attempted,
virus was lost between the transfer of supernatant to the subculture
plate and final transfer of supernatants and cells into flasks.
Multiple wells containing single foci were identified. However,
corresponding cells and supernatants did not yield infectious virus.
To enhance virus adsorption to the cells in the subculture plate, the
plaque-purification protocol developed by Remington et al. was
modified (41). Before transferring the supernatants from the
culture plate to the subculture plate, the CrFK cells on the
subculture plate were treated with serum-free medium containing 8
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^g/ml of DEAE dextran for 20 minutes. DEAE dextran treatment
coats the cells with a positive charge, thereby making the cells
more attractive to the negative charged virus particles. Using this
modification, supernatants from eighteen isolates were transferred
onto the DEAE dextran-treated CrFK cells of the subculture plate.
When the cells and supernatants were transferred to flasks, virus
was detected in one of the eighteen cultures. This virus, designated
DCR-Sc, was ddC-resistant (Figure 6) and was characterized against
a battery of RT inhibitors.

SUSCEPTIBILITY OF ddC-RESISTANT AND 34TF10 FIV TO ddC
Susceptibility of virus from each round of selection to ddC
was assayed with the FIA by determining the number of foci at
varying concentrations of ddC. The data shown in Figure 5 verify
that DCR-Zc was considerably less sensitive to inhibition by ddC
than the molecular clone. The

IC50

value for inhibition of DCR-2c by

ddC was greater than 25 /L/M compared to 5 /JM for FIV34TF10. These
data confirmed that DCR-2c was at least 5-fold less susceptible to
ddC than the molecular clone. DCR-5c, the plaque-purified mutant
derived from DCR-2c, was also less sensitive to inhibition by ddC
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Figure 6. Inhibition of FiV 34TF10 and DCR-5c by various antivirals
as determined by focal infectivity assay. Results are from three
experiments and each point represents four determinations. Bars
represent standard error of the mean, and are omitted where the
standard error was to small to accurately show using error bars.
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than FIV 34TF10. The dose response curve shown In Figure 6
verified that the
greater than 12

IC50

value for inhibition of DCR-5c by ddC was

compared to 3

for the molecular clone.

CHARACTERIZATION OF ddC-RESISTANT MUTANT
Susceptibility to antiviral compounds.

The susceptibility of

virus from each round of selection to a variety of other antiviral
compounds was determined using the FIA and compared to the
susceptibilities of wild-type virus (Table 1). These data showed
that DCR-Zc is cross-resistant to ddl and PFA. DCR-2c is also
slightly less sensitive to 3TC than wild-type FIV 34TF10. The
mutant FIV was similar to FIV 34TF10 in sensitivity to AZT and
PMEA. Of the compounds tested, the mutant exhibited resistance to
a similar dideoxynucleoside analog (ddl), and, interestingly, to a
non-nucleoside analog (PFA). The

IC50

value for inhibition of DCR-2c

by ddl was greater than 13 ^/M compared to 3 jwM for FIV34TF10.
DCR-Zc demonstrated an

IC50

value for PFA of greater than 400 uM

compared to 75 pM for FIV 34TF10. The

IC50

values obtained for

inhibition of FIV 34TF10 and ddC-resistant FIV are summarized in
Table 1.
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The drug susceptibility of DCR-5c was determined to confirm
that the phenotype of the mutant had not changed during plaquepurification. The sensitivities to ddC, ddl, AZT, PFA, PMEA, and 3TC
of this plaque-purified mutant were compared to the molecular
clone (Figure 6 and Table 2). Referring back to Table 1, it can be
seen that the phenotype of the plaque-purified mutant (DCR-5c)
remained similar to the mutant population (DCR-2c). The plaquepurified mutant demonstrated resistance to ddC, ddl and PFA, slight
resistance to 3TC, and wild-type sensitivities to all other drugs
tested.
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Table 2. Sensitivities of FIV 34TF10 and DCR-5c to antiviral
compounds, as determined by FIAa.

Mean IC5oG/M)+SE

Compound

FIV3 4TF10

DCR- 5 C

ddC

3.5+0.6

13±0.6

ddl

3.0+0.4

9.8+0.5

AZT

0.3+0.2

0.5+0.1

PFA

78±9.0

>600

PMEA

0.3+0.1

0.5+0.1

3TC

0.5+0.1

0.8±0.1

a Values are from three experiments, with four determinations per
experiment.

Reverse transcriptase.

Reverse transcriptase was purified from

DCR-Sc and the kinetic parameters of inhibition by ddCTP were
determined and compared to the wild-type FIV RT (R-RT). As
expected, ddCTP displayed competitive inhibition of the enzymes
(Figure 7). The wild-type FIV RT was produced in Escherichia coli,
and has been shown to be similar to virion-derived FIV RT in

ddCTP KJ for R^T (ri-dC)
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Figure 7. Determination of Kj values for inhibition of wild-type
recombinant RT and DCR-5c RT. Values reported are averages from
duplicate determinations.

44
susceptibility to ddCTP and other antiviral nucleotides (31). The
two enzymes had comparable Km values for both dTTP and dCTP.
However, the mutant enzyme was ten times less sensitive to ddCTP
compared to the recombinant RT. Wild-type FIV RT had an
of 49 nM compared to the mutant RT

IC50

IC50

value

value of 456 nM (Figure 7,

Table 3). Future experiments should determine whether the mutant
RT is susceptibility to ddATP (the active form of ddl), PFA, and
AZTTP.

Table 3. Comparison of kinetic constants for RT from FIV 34TF10
and DCR-5ca.

FIV

Km for dCTP
(juM)

Kj for ddCTP
(nM)

K/Km

34TF10

6.2±1.3

49±2.3

.008

DCR-5C

11±1.2

456±27

.04

a Values are means + standard error from 2 or more determinations.
Nucleotide sequence analysis.

Sequence analyses of the RT-encoding

region of the pol gene from DCR-5c and FIV 34TF10 were performed
in the forward and reverse directions. The results are shown in Fig.
8. FIV 34TF10 DNA had been subcloned into the
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Figure 8. Nucleotide sequence and deduced amino acid sequence of
RT-encoding region of pol gene from 34TF10 clone of FIV in pUCI 19,
virus derived from this molecular clone, and DCR-5c.
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plasmid pUCI 19 and was used as a sequencing wild-type control.
The sequence of DCR-5c was identical to the 34TF10 clone of FIV in
pUC119 and virus derived from this molecular clone except for a
single point mutation at position 2342 of a G to a C. This resulted in
the replacement of aspartate with histidine at the third amino acid
of RT, which produced a negative to positive change in the amino
acid charge.
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DISCUSSION
We report the first successful selection of a ddC-reslstant
mutant of FIV. This was the first ddC-resistant mutant from a
molecular clone of either FIV or HIV-1. This mutant was selected by
the method developed by Remington et al. (41) using a drug
concentration that is known to completely inhibit replication of
wild-type FIV in vitro. This ddC-resistant mutant of FIV proved to
be unique in several ways. First, DCR-2c was not detectable in cell
culture until 17 weeks post-infection. This is at least twice the
length of time it takes for selection of mutants to AZT, ddl, PFA or
3 '-fluoro-3 '-deoxythymidine (FLT) (3-8 weeks). Although no direct
correlations to the clinical setting can be drawn, at least within our
well-defined cell culture system, It appears that ddC resistance
arises more slowly than to other RT inhibitors.

The second unique quality of DCR-2c was the difficulty it
posed in plaque-purification. Using the established plaquepurification protocol developed by our lab, I was unable to obtain
virus production in four attempts starting with 30 possible single
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foci. Even with the modified version, only one culture produced
virus out of eighteen possible single foci.

DCR-2c is the only drug-

resistant mutant selected by our lab that was difficult to plaquepurify.

The reason for this difficulty in plaque-purification is not

known.

Thirdly, it is interesting that both DCR-2c and DCR-5c
exhibited unusually high titers when virus was finally produced. The
high titer displayed by the ddC-resistant mutants was in stark
contrast to the other drug resistant mutants selected by our lab,
most of which yielded titers 5 to! 0-fold lower.

The plaque-purified ddC-resistant mutant of FIV, DCR-5c,
demonstrated similar phenotypes when compared to the mutant
population, OCR-2c. In addition, DCR-5c showed some similarities
to the ddC-resistant mutant of HIV-1 selected by Gu et al. (20).
Both DCR-Sc and the HIV-1 mutant demonstrated cross-resistance
to ddl and wild-type susceptibility to AZT (20). However, DCR-5c
exhibited only a slight resistance to 3TC, whereas Gu et al. reported
a 500-fold resistance of the HIV-1 mutant to 3TC (20). These

51
differences may be due to the different selection methods used to
select HIV-1 drug resistant mutants. The HIV-1 mutants were
selected by gradually increasing drug concentrations in a step-wise
method during the selection process. This protocol has been used
because researchers have had difficulty selecting mutants of HIV-1
with high drug concentrations, as used in FIV selections. Gu et al.
did not test inhibition by PMEA or PFA, so we cannot compare these
phenotypes. In addition to the similarities in the two mutants
susceptibility to ddC and ddl, the RTs of the two mutants were also
similar in that they were resistant to ddCTP.

Reverse transcriptases were purified from wild-type and the
plaque-purified ddC-resistant mutant (DCR-5c) of FIV. The RT from
the mutant virus was resistant to the active form of ddC, ddCTP,
compared with wild-type RT.

DCR-5c showed a ten-fold increase of

resistance. This compares to the 20-fold Increase of resistance
shown by the ddC-resistant mutant of HIV-1 that Gu et al. described
(19.). Assays of both RTs used poly(rl)-oligo(dC) as template-primer
and dCTP as substrate.

Although the RT appears to show a higher

resistance to ddCTP than the virus replication did to ddC, the ratio

Kj/Km used to normalize for changes in substrate recognition by the
enzyme was increased approximately 5-fold with the mutant virus.
These findings are consistent with the 5-fold increase in
inhibition of replication of OCR-5c by ddC.

IC50

for

It appears that the

mutation in the RT-encoding region confers resistance to ddC.
Although it may seem intuitive that the RT of a drug-resistant
mutant would be resistant to the ddNTP, this has not always been
the case. Many studies have described isolation or selection of drug
resistance FIV and HIV-1 that had RTs susceptible to the ddNTPs
(26,41,55).

The resistance shown by the RT from DCR-5c can be correlated
to sequence analysis. The ddC-resistant mutant that was derived
from the 34TF10 clone of FIV enabled examination of the nucleotide
sequence of ddC-resistant FIV. Sequence analysis of the RTencoding region of the pol gene revealed a single base change in the
mutant FIV, as compared to the FIV34TF10 wild-type. The
nucleotide substitution at position 2342 in DCR-5c was the only
divergence from the wild-type RT-encoding region. This
substitution produced an asp-3 to a his amino acid change, resulting
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in a negative to positive charge alteration. This is a significant
change that would possibly result in a conformational modification
of the RT. Asp-3 resides in an area analogous to where the
template-primer binds during DNA elongation within the HIV-1 RT
(23). This is based on HIV-1 structure and assumptions of
similarities. Because of the RT data, it is likely that this mutation
within RT is responsible for the ddC-resistance. No drug-resistance
mutation has previously been mapped to this area in either FIV or
HIV-1. This mutation in DCR-5c provides information regarding
possible new sites for drug resistance.

Some of the mutations responsible for ddC-resistance of HIV1 are also located within the finger-like domain of RT (15,16,19,20).
Although the codon 3 of the ddC-resistant mutant is located close to
the amino terminus end, it also is located within the finger-like
domain, and therefore is in position to interact with the templateprimer. Boyer et al. proposed that resistance to the
dideoxynucleotide inhibitors results from a repositioning or change
in the conformation of the template-primer that alters the ability of
the enzyme to select or reject an incoming dNTP (3).
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Conduisions and future directions.

We have successfully

selected a ddC-reslstant mutant of FIV by culture of FIV in the
presence of a high concentration of ddC (41). In order to further
characterize ddC-resistant mutants with respect to the HIV-1
mutants, it would be useful to perform a step-wise ddC selection
with FIV, under conditions similar to those used by Gao et al (16).
Comparison of selection methods would answer whether selection
methods play a role in the phenotype and genotype of drug resistant
mutants. In addition, it would be extremely interesting to determine
the susceptibility of RT from DCR-5c to ddATP, the active form of
ddl, AZTTP, and PFA. The results from these experiments could
confirm that the RT does in fact confer the phenotype of the whole
virus.

Reversion and/or site-directed mutagenesis studies would provide
additional confirmation whether the single point mutation is
responsible for resistance of the RT to ddCTP and the virus to ddC.
Reversion studies would also provide information on the stability of
the drug-resistant population.
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Lastly, in vivo studies would be especially useful for pathogenicity
studies. Due to the similarities between FIV and HIV-1, in vivo
studies would provide information on whether ddC-resistant
mutants are pathogenic.
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